Quince Therapeutics, Inc. Share Price & Technical Analysis
QNCX · $1.10 (+2.80%)
Healthcare / Biotechnology
$1.10
+2.80%
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by muta…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-15% return in May, -10% avg return in past 3 year May month.
-108% return in 2026, 98% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -95% | -19% | -9% | 30% | -15% | – | – | – | – | – | – | – | -108% |
| 25 | -14% | -10% | -11% | -17% | -7% | 56% | 2% | -4% | 0% | 1% | 120% | -7% | 109% |
| 24 | 18% | 5% | -18% | -6% | -20% | -16% | 7% | -8% | 11% | 113% | 26% | -7% | 105% |
| 23 | 53% | -5% | 68% | -5% | -2% | 1% | -19% | 8% | -16% | -10% | -6% | 15% | 81% |
| 22 | -52% | -29% | 41% | -41% | -30% | -16% | -14% | -11% | -23% | -27% | -26% | -15% | -241% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$19.81M
P/E ratio
—
52W high
$45.50
52W low
$0.79
Volume
12,29,399
Beta
1.46
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Quince Therapeutics, Inc. share price today?
- Quince Therapeutics, Inc. (QNCX) last traded around $1.10 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does QNCX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for QNCX. Download the app for real-time alerts.
- How can I analyze Quince Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.